Promising phase III trial paves the way for alemtuzumab approval.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coles, A. J. et al. New Engl. J. Med. 359, 1786-1801 (2008).
Jones, J. L. et al. Brain 133, 2232-2247 (2010).
Rights and permissions
About this article
Cite this article
Graham-Rowe, D. Antibody offers hope for multiple sclerosis treatment. Nature (2011). https://doi.org/10.1038/news.2011.609
Published:
DOI: https://doi.org/10.1038/news.2011.609